Navigation Links
Quanterix Announces New Technology Evaluation Agreement
Date:2/22/2011

CAMBRIDGE, Mass., Feb. 22, 2011 /PRNewswire/ -- Quanterix Corporation, enabling a new generation of diagnostic tests based on revolutionary Single Molecule Array (SiMoA™) technology, today announced that it has entered into an evaluation agreement with Novartis Diagnostics on the potential use of Quanterix's SiMoA platform technology for diagnostic use.  The evaluation will be conducted at Quanterix and will focus on an undisclosed neuron-specific protein target.

"We are excited to initiate this technology evaluation with Novartis, one of the world's leading healthcare companies," said David Okrongly, Ph.D., Quanterix President and Chief Executive Officer.  "This partnership is an important milestone for Quanterix, and another step toward our goal to be the recognized global leader in sensitive and precise detection technology.  Through this collaborative project, we hope to leverage the 1000-fold sensitivity improvement of SiMoA technology to develop a novel class of valuable diagnostic tests that will provide greater insight into disease and improve patient outcomes."

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology.  SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring.  Automated systems based on SiMoA are being designed to provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness.  Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures.  For additional information, please visit www.quanterix.com.


'/>"/>
SOURCE Quanterix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board
2. Stereotaxis Announces Election of Joseph D. Keegan to Board of Directors
3. China Cord Blood Corporation Announces Results of 2010 Annual General Meeting
4. Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
5. Sensus Healthcare Announces Its Exhibitor Attendance at the 9th Annual South Beach Symposium™
6. Sensus Healthcare Announces the Formation of a Medical Advisory Board
7. Sigma-Aldrich Announces Organizational Changes
8. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
9. MiMedx Announces Launch of AmnioFix™
10. Savient Pharmaceuticals Announces Executive Appointments
11. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... ... Borlaug CAST Communication Award goes to Jayson Lusk, a consummate communicator who promotes ... media to advocate for science, as he explains how innovation and growth in ...
(Date:4/26/2017)... SAN DIEGO, CALIF. (PRWEB) , ... April 26, ... ... Mother’s Day? Lajollacooks4u, San Diego’s premiere team-building and cooking events company, offers ... cooking classes. , Menus specialize in California cuisine, and guests leave inspired ...
(Date:4/26/2017)... ... April 25, 2017 , ... LABS, Inc. (LABS) announced in December 2016 ... extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) specific ... offer NAT screening for blood donors under an Investigational New Drug (IND) study protocol. ...
(Date:4/26/2017)... Va. (PRWEB) , ... April 26, 2017 , ... ... make headlines and drive high-level conversations among healthcare industry stakeholders, the discussion surrounding ... Environment – taking place May 15-18, 2017 in Los Angeles, Calif. Hosted by ...
Breaking Biology Technology:
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
Breaking Biology News(10 mins):